Aria CV

Aria CV is pioneering a unique, purely mechanical implantable device to treat Pulmonary Arterial Hypertension (WHO Group 1 PH), a progressive and deadly cardiovascular condition. Its core technology mimics the natural elasticity of a healthy pulmonary artery, using a gas-filled balloon and reservoir system driven by the heart's own motion to improve vascular compliance and cardiac efficiency. The company has completed an acute first-in-human study and is led by a seasoned medical device CEO alongside its scientific founders. As an investigational-stage company, Aria CV is navigating the clinical and regulatory pathway to bring this innovative, device-based therapy to a large, underserved patient population.

Passive, non-electronic implantable device that uses a gas-filled balloon and reservoir system, driven by cardiac motion, to restore compliance to the pulmonary artery.

Aria CV's primary competition is from established and emerging pharmaceutical therapies for PAH. Direct device competition is limited, though other device approaches (e.g., pulmonary artery denervation) are in development. The company's key differentiator is its purely passive, motion-driven mechanism, which avoids the complexities of batteries, pumps, or electronics associated with other implantable cardiac devices.